We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversifybeyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others. Meanwhile, in Feb 2017, the company spinned-off its hemophilia business which allows it to focus on neurology, its key area of expertise.
BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 6.91%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s first quarter 2018 earnings beat expectations. The company posted earnings of $6.05 per share while our consensus called for EPS of $5.93.
Revenues Miss: Biogen posted revenues of $3.13 billion, marginally missing the consensus estimate of $3.15 billion. Revenue increased 11% year over year. Excluding hemophilia business revenues grew 15% during the same period.
Key Statistics: The company's oral MS drug Tecfidera sales increased 3% year over year but decreased 8% sequentially to $987 million. The other MS drug, Tysabri’s sales decreased 15% year over year to $462 million but was flat sequentially.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Biogen (BIIB) Q1 Earnings Beat, Sales Miss
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) holds a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. However, as competition in the MS market intensifies, Biogen is trying to diversifybeyond MS to other areas like Alzheimer's, Parkinson's, stroke, among others. Meanwhile, in Feb 2017, the company spinned-off its hemophilia business which allows it to focus on neurology, its key area of expertise.
BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 6.91%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s first quarter 2018 earnings beat expectations. The company posted earnings of $6.05 per share while our consensus called for EPS of $5.93.
Revenues Miss: Biogen posted revenues of $3.13 billion, marginally missing the consensus estimate of $3.15 billion. Revenue increased 11% year over year. Excluding hemophilia business revenues grew 15% during the same period.
Key Statistics: The company's oral MS drug Tecfidera sales increased 3% year over year but decreased 8% sequentially to $987 million. The other MS drug, Tysabri’s sales decreased 15% year over year to $462 million but was flat sequentially.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>